Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01662921 · ClinicalTrials.gov registry record · Phase 2
Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes
A Phase 2 study, sponsored by Sansum Diabetes Research Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01662921 is a Phase 2 study that has completed, run by Sansum Diabetes Research Institute. The registered enrollment target is 17 participants.
The verdict
NCT01662921, a Phase 2 study, has completed, sponsored by Sansum Diabetes Research Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
We hypothesize that insulin glulisine is non-inferior to currently proven rapid-acting insulin lispro when used in a basal/bolus regimen to treat hyperglycemia in patients with gestational diabetes mellitus.
Interventions
- DRUG Insulin glulisine
- DRUG Insulin LISPRO
- DRUG NPH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01662921
The ClinicalTrials.gov registry entry for NCT01662921 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sansum Diabetes Research Institute, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Insulin glulisine is the first listed.
NCT01662921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01662921 about?
NCT01662921 is a clinical study titled "Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes". We hypothesize that insulin glulisine is non-inferior to currently proven rapid-acting insulin lispro when used in a basal/bolus regimen to treat hyperglycemia in patients with gestational diabetes mellitus.
What is the current status of trial NCT01662921?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2013-04. Estimated completion is 2015-08-31.
What interventions are being tested in trial NCT01662921?
The interventions under investigation include: Insulin glulisine (DRUG), Insulin LISPRO (DRUG), NPH (DRUG).
Who is sponsoring clinical trial NCT01662921?
This trial is sponsored by Sansum Diabetes Research Institute, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.